Upgrade to SI Premium - Free Trial

Mizuho Securities Upgrades Audentes Therapeutics (BOLD) to Buy

August 8, 2018 5:03 AM
Mizuho Securities upgraded Audentes Therapeutics (NASDAQ: BOLD) from Neutral to Buy with a price target of $45.00 (from $38.00).Analyst Difei ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Upgrades